- Home
- IH vs ADAG Comparison
IH vs ADAG Comparison
Compare IH & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IH | ADAG |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | China | China |
| Employees | 558 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 222.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IH | ADAG |
|---|---|---|
| Price | $1.15 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 5.2K | ★ 222.2K |
| Earning Date | 03-31-2026 | 04-01-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $1.44 |
| 52 Week High | $3.09 | $4.85 |
Technical Indicators
Market Signals| Indicator | IH | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 36.31 |
| Support Level | N/A | $2.78 |
| Resistance Level | $1.38 | $3.19 |
| Average True Range (ATR) | 0.04 | 0.30 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 35.71 | 18.18 |
Price Performance
Historical ComparisonAbout IH iHuman Inc.
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.